06/07/2024 3:30 PM | Syros Pharmaceuticals (Issuer) WIRTH PETER (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/07/2024 3:30 PM | AKKARAJU SRINIVAS (Reporting) Syros Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/07/2024 3:30 PM | Fanucci Marsha (Reporting) Syros Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/07/2024 3:30 PM | OH ANDREW M. (Reporting) Syros Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/07/2024 3:30 PM | Eckhardt Sue Gail (Reporting) Syros Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/07/2024 3:30 PM | Dunsire Deborah (Reporting) Syros Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/07/2024 3:30 PM | Syros Pharmaceuticals (Issuer) TYSON TIMOTHY (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
|
06/07/2024 3:30 PM | Syros Pharmaceuticals (Issuer) Young Richard A (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/07/2024 3:30 PM | Simonian Nancy A (Reporting) Syros Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/06/2024 3:30 PM | Syros Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
06/04/2024 3:41 PM | AKKARAJU SRINIVAS (Reporting) AKKARAJU SRINIVAS (Reporting) Syros Pharmaceuticals (Issuer) Syros Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/14/2024 5:42 AM | Syros Pharmaceuticals (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
04/23/2024 6:01 AM | Syros Pharmaceuticals (Filer)
| Form DEF 14A | |
04/23/2024 6:05 AM | Syros Pharmaceuticals (Filer)
| Form DEFA14A | |
04/23/2024 6:10 AM | Syros Pharmaceuticals (Filer)
| Form ARS | |
04/12/2024 3:30 PM | Syros Pharmaceuticals (Filer)
| Form PRE 14A | |
04/05/2024 3:30 PM | Roth David (Reporting) Syros Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
04/02/2024 3:54 PM | Haas Jason (Reporting) Syros Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
04/02/2024 3:57 PM | Quirk Gerald E (Reporting) Syros Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
04/02/2024 3:58 PM | Roth David (Reporting) Syros Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
04/02/2024 3:59 PM | Simonian Nancy A (Reporting) Syros Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
04/02/2024 4:01 PM | Stephens Kristin (Reporting) Syros Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
04/02/2024 3:14 PM | Roth David (Reporting) Syros Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
03/27/2024 6:04 AM | Syros Pharmaceuticals (Filer)
| Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
03/27/2024 5:49 AM | Syros Pharmaceuticals (Filer)
| Form 10-K Annual report pursuant to Section 13 or 15(d) | |
02/14/2024 7:56 PM | Blue Owl Capital Holdings LP (Filed by) Syros Pharmaceuticals (Subject)
| Form SC 13G | |
02/13/2024 7:22 PM | Avidity Partners Management LP (Filed by) Syros Pharmaceuticals (Subject)
| Form SC 13G/A | |
02/13/2024 5:59 PM | Bain Capital Life Sciences Fund II, L.P. (Filed by) Syros Pharmaceuticals (Subject)
| Form SC 13G/A | |
02/13/2024 6:02 PM | Ally Bridge MedAlpha Master Fund L.P. (Filed by) Syros Pharmaceuticals (Subject)
| Form SC 13G/A | |
02/09/2024 4:08 PM | Artal International S.C.A. (Filed by) Syros Pharmaceuticals (Subject)
| Form SC 13G/A | |
02/07/2024 6:09 AM | ADAGE CAPITAL PARTNERS GP, L.L.C. (Filed by) Syros Pharmaceuticals (Subject)
| Form SC 13G/A | |
01/08/2024 6:06 AM | Syros Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
01/02/2024 3:15 PM | Point72 Asset Management, L.P. (Filed by) Syros Pharmaceuticals (Subject)
| Form SC 13G | |
12/26/2023 4:19 PM | Samsara BioCapital, L.P. (Filed by) Syros Pharmaceuticals (Subject)
| Form SC 13D/A | |
12/26/2023 4:24 PM | AKKARAJU SRINIVAS (Reporting) Syros Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/19/2023 3:53 PM | Syros Pharmaceuticals (Filer)
| Form 424B5 | |
12/19/2023 3:59 PM | Syros Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
12/14/2023 3:24 PM | Roth David (Reporting) Syros Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/12/2023 3:12 PM | Roth David (Reporting) Syros Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
12/08/2023 3:23 PM | Roth David (Reporting) Syros Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/06/2023 6:05 AM | Syros Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
Write this ticker symbol down… (Ad) A megatrend now poised to mint a brand-new wave of millionaires right here in America.
And today, self-made millionaire Tim Bohen is giving you an inside look at the megatrend that’s going to change everything. Discover the #1 company leading this revolution |
12/05/2023 4:23 PM | Simonian Nancy A (Reporting) Syros Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/05/2023 4:28 PM | Chee Conley (Reporting) Syros Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
11/14/2023 5:47 AM | Syros Pharmaceuticals (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
11/02/2023 3:51 PM | Chee Conley (Reporting) Syros Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
11/02/2023 3:52 PM | Stephens Kristin (Reporting) Syros Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
11/02/2023 3:52 PM | Roth David (Reporting) Syros Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
10/20/2023 3:15 PM | Samsara BioCapital, L.P. (Filed by) Syros Pharmaceuticals (Subject)
| Form SC 13D | |
10/20/2023 3:23 PM | Quirk Gerald E (Reporting) Syros Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
10/02/2023 7:49 AM | Syros Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
09/19/2023 3:46 PM | AKKARAJU SRINIVAS (Reporting) Syros Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/19/2023 3:47 PM | Alles Mark J (Reporting) Syros Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/19/2023 3:48 PM | Syros Pharmaceuticals (Issuer) Young Richard A (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/14/2023 3:05 PM | Quirk Gerald E (Reporting) Syros Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/08/2023 5:53 AM | Syros Pharmaceuticals (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
07/31/2023 3:12 PM | Roth David (Reporting) Syros Pharmaceuticals (Subject) Syros Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/21/2023 3:36 PM | Syros Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
07/18/2023 7:27 PM | Olson Eric R (Reporting) Syros Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
07/17/2023 3:00 PM | Olson Eric R (Reporting) Syros Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |